AIT Bioscience, PreClinOmics forge working partnership
The partnership between the two life sciences companies allows a pharmaceutical or biotech company investigating new drug candidates or existing products the ability to have their compounds dosed in rodent models in about seven days after the first client meeting. “Our resources and processes are built around speed because clients need their data quicker to make their decisions which also provides cost efficiencies,” said PreClinOmics chairman and CEO Joe Pesek.
“Our two companies provide an unmatched convenience to a customer due to the fact we are located about a mile from each other, we have complementary expertise, and we can work concurrently rather than serially to save the customer time. A client can visit both companies in the same day,” said AIT Bioscience executive director Ronald Shoup, Ph.D.
As a result of their expertise and collaboration, the two companies are able to provide a client with an earlier impression as to whether their compound is being absorbed and distributed as expected. “A customer may have only worked with their compound in chemical tests which would give them no idea as to the absorption rate of the drug or if it is reaching its intended target,” said Shoup. “PreClinOmics is able to design the experiments and offer consultation on the study design, while AIT Bioscience works on the kind of analyses that must be done.”